Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527858 · ClinicalTrials.gov registry record · Phase 2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT07527858 is a Phase 2 study that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 170 participants.
The verdict
NCT07527858, a Phase 2 study, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG Denikitug
- DRUG Trifluridine-Tipiracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2026-05-19 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07527858
The ClinicalTrials.gov registry entry for NCT07527858 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07527858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07527858 about?
NCT07527858 is a clinical study titled "Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer". The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of ...
What is the current status of trial NCT07527858?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2026-05-19. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07527858?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), Denikitug (DRUG), Trifluridine-Tipiracil (DRUG).
Who is sponsoring clinical trial NCT07527858?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.